SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '1k2p'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1ICU_C_NIOC225_1 (OXYGEN-INSENSITIVE NAD(P)H NITROREDUCTASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 6	SER A 578 PHE A 574 PHE A 559 GLU A 567	None	1.08A	1icuC-1k2pA: 0.0 1icuD-1k2pA: 0.0	1icuC-1k2pA: 20.36 1icuD-1k2pA: 20.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1JLF_A_NVPA999_1 (HIV-1 RT A-CHAIN HIV-1 RT B-CHAIN)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 8	LEU A 486 VAL A 529 CYH A 527 GLY A 480	None	0.99A	1jlfA-1k2pA: undetectable 1jlfB-1k2pA: 1.0	1jlfA-1k2pA: 18.05 1jlfB-1k2pA: 19.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1M17_A_AQ4A999_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	ALA A 428 LYS A 430 THR A 474 MET A 477 GLY A 480 LEU A 528 ASP A 539	None	0.57A	1m17A-1k2pA: 30.0	1m17A-1k2pA: 32.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1MXD_A_ACRA733_1 (ALPHA AMYLASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 6	SER A 553 THR A 552 LEU A 547 ASP A 548	None	1.23A	1mxdA-1k2pA: undetectable	1mxdA-1k2pA: 18.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1RXC_B_URFB2011_1 (URIDINE PHOSPHORYLASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 8	THR A 474 GLY A 462 ILE A 472 VAL A 463	None	0.72A	1rxcB-1k2pA: undetectable	1rxcB-1k2pA: 19.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1RXC_E_URFE2031_1 (URIDINE PHOSPHORYLASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 8	THR A 474 GLY A 462 ILE A 472 VAL A 463	None	0.79A	1rxcE-1k2pA: undetectable	1rxcE-1k2pA: 19.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1RXC_I_URFI2041_1 (URIDINE PHOSPHORYLASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 8	THR A 474 GLY A 462 ILE A 472 VAL A 463	None	0.78A	1rxcI-1k2pA: undetectable	1rxcI-1k2pA: 19.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1RXC_K_URFK2061_1 (URIDINE PHOSPHORYLASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 8	THR A 474 GLY A 462 ILE A 472 VAL A 463	None	0.70A	1rxcK-1k2pA: undetectable	1rxcK-1k2pA: 19.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XF1_A_ACTA1107_0 (C5A PEPTIDASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 5	LEU A 402 GLY A 419 ILE A 473 PHE A 471	None	0.91A	1xf1A-1k2pA: undetectable	1xf1A-1k2pA: 16.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XKK_A_FMMA91_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	ALA A 428 MET A 449 THR A 474 GLY A 480 CYH A 481 ASP A 539 PHE A 540	None	1.03A	1xkkA-1k2pA: 29.5	1xkkA-1k2pA: 31.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XKK_A_FMMA91_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	9 / 12	ALA A 428 THR A 474 GLY A 480 CYH A 481 LEU A 483 ARG A 487 LEU A 528 ASP A 539 PHE A 540	None	0.91A	1xkkA-1k2pA: 29.5	1xkkA-1k2pA: 31.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_A_STIA600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 6	LEU A 408 LYS A 430 VAL A 458 ILE A 472	None	0.88A	2hyyA-1k2pA: 29.4	2hyyA-1k2pA: 45.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2W3B_B_FOLB401_1 (DIHYDROFOLATE REDUCTASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	3 / 3	GLU A 441 GLN A 467 ARG A 468	None	0.81A	2w3bB-1k2pA: undetectable	2w3bB-1k2pA: 22.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y6O_A_1N1A1892_1 (EPHRIN TYPE-A RECEPTOR 4)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	ALA A 428 LYS A 430 ILE A 472 THR A 474 TYR A 476 GLY A 480 LEU A 528 SER A 538	None	0.72A	2y6oA-1k2pA: 26.5	2y6oA-1k2pA: 39.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_A_B49A1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 12	VAL A 416 ALA A 428 MET A 477 GLY A 480 LEU A 528 ASP A 539	None	0.54A	2y7jA-1k2pA: 19.3	2y7jA-1k2pA: 22.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_B_B49B1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 10	VAL A 416 ALA A 428 MET A 477 GLY A 480 LEU A 528 ASP A 539	None	0.55A	2y7jB-1k2pA: 19.9	2y7jB-1k2pA: 22.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2YFX_A_VGHA9000_1 (TYROSINE-PROTEIN KINASE RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 8	ALA A 428 MET A 477 GLY A 480 LEU A 528	None	0.19A	2yfxA-1k2pA: 28.8	2yfxA-1k2pA: 34.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ZVA_A_1N1A513_1 (TYROSINE-PROTEIN KINASE LYN)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	ALA A 428 LYS A 430 VAL A 458 ILE A 472 THR A 474 MET A 477 GLY A 480 LEU A 528	None	0.50A	2zvaA-1k2pA: 27.8	2zvaA-1k2pA: 41.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3AOX_A_EMHA901_1 (ALK TYROSINE KINASE RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 10	ALA A 428 LYS A 430 VAL A 458 MET A 477 GLY A 480 LEU A 528	None	0.53A	3aoxA-1k2pA: 28.3	3aoxA-1k2pA: 33.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3BBT_B_FMMB91_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	ALA A 428 LEU A 460 THR A 474 GLY A 480 LEU A 528 ASP A 539 PHE A 540	None	0.74A	3bbtB-1k2pA: 29.3	3bbtB-1k2pA: 34.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3BBT_B_FMMB91_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	VAL A 416 ALA A 428 MET A 449 LEU A 460 GLY A 480 LEU A 528 ASP A 539 PHE A 540	None	0.74A	3bbtB-1k2pA: 29.3	3bbtB-1k2pA: 34.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 10	LEU A 408 VAL A 416 LYS A 430 VAL A 458 ILE A 472 VAL A 537	None	0.91A	3cs9A-1k2pA: 25.6	3cs9A-1k2pA: 45.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	ALA A 428 LEU A 457 THR A 474 GLY A 480 PHE A 517 HIS A 519 LEU A 528	None	0.66A	3cs9A-1k2pA: 25.6	3cs9A-1k2pA: 45.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_B_NILB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 9	LEU A 408 VAL A 416 LYS A 430 VAL A 458 ILE A 472 LEU A 528 VAL A 537	None	1.04A	3cs9B-1k2pA: 29.0	3cs9B-1k2pA: 45.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_C_NILC600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	5 / 12	ALA A 428 LEU A 457 THR A 474 PHE A 517 HIS A 519	None	0.78A	3cs9C-1k2pA: 28.9	3cs9C-1k2pA: 45.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_C_NILC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 9	LEU A 408 VAL A 416 LYS A 430 VAL A 458 ILE A 472 VAL A 537	None	0.89A	3cs9C-1k2pA: 28.9	3cs9C-1k2pA: 45.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_D_NILD600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 12	ALA A 428 LEU A 457 THR A 474 GLY A 480 PHE A 517 HIS A 519	None	0.59A	3cs9D-1k2pA: 25.6	3cs9D-1k2pA: 45.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G0E_A_B49A9000_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 11	LEU A 408 VAL A 416 ALA A 428 VAL A 458 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.78A	3g0eA-1k2pA: 26.6	3g0eA-1k2pA: 34.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G0F_A_B49A9001_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 11	VAL A 416 ALA A 428 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.74A	3g0fA-1k2pA: 24.1	3g0fA-1k2pA: 34.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G0F_B_B49B9001_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 10	VAL A 416 ALA A 428 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.64A	3g0fB-1k2pA: 27.2	3g0fB-1k2pA: 34.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G5D_A_1N1A1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	VAL A 416 ALA A 428 VAL A 458 ILE A 472 TYR A 476 GLY A 480 LEU A 528	None	0.53A	3g5dA-1k2pA: 26.5	3g5dA-1k2pA: 39.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G5D_B_1N1B1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	VAL A 416 ALA A 428 LYS A 430 VAL A 458 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.63A	3g5dB-1k2pA: 26.5	3g5dB-1k2pA: 39.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K54_A_1N1A1_1 (TYROSINE-PROTEIN KINASE BTK)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	9 / 12	ALA A 428 LYS A 430 VAL A 458 ILE A 472 THR A 474 TYR A 476 GLY A 480 LEU A 528 SER A 538	None	0.64A	3k54A-1k2pA: 29.4	3k54A-1k2pA: 99.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K5V_B_STIB2_2 (TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 6	LEU A 408 LYS A 430 VAL A 458 ILE A 472	None	0.90A	3k5vB-1k2pA: 28.4	3k5vB-1k2pA: 44.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3LXK_A_MI1A1125_1 (TYROSINE-PROTEIN KINASE JAK3)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	LEU A 408 VAL A 416 ALA A 428 LYS A 430 VAL A 458 TYR A 476 CYH A 481	None	0.80A	3lxkA-1k2pA: 30.3	3lxkA-1k2pA: 29.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MIY_A_B49A1_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 11	ALA A 428 LYS A 430 MET A 477 GLY A 480 LEU A 528 ASP A 539	None	0.76A	3miyA-1k2pA: 26.8	3miyA-1k2pA: 57.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MIY_A_B49A1_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 11	ALA A 428 VAL A 458 MET A 477 GLY A 480 LEU A 528 SER A 538 ASP A 539	None	0.83A	3miyA-1k2pA: 26.8	3miyA-1k2pA: 57.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_D_STID1_2 (TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 6	VAL A 416 LYS A 430 VAL A 458 ILE A 472	None	0.78A	3mssD-1k2pA: 28.9	3mssD-1k2pA: 44.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OCT_A_1N1A663_1 (TYROSINE-PROTEIN KINASE BTK)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	LEU A 408 VAL A 416 LYS A 430 MET A 449 VAL A 458 GLY A 480 GLU A 488 LEU A 528	None	1.10A	3octA-1k2pA: 14.5	3octA-1k2pA: 99.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OCT_A_1N1A663_1 (TYROSINE-PROTEIN KINASE BTK)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	LEU A 408 VAL A 416 LYS A 430 VAL A 458 TYR A 476 GLY A 480 GLU A 488 LEU A 528	None	0.93A	3octA-1k2pA: 14.5	3octA-1k2pA: 99.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OCT_A_1N1A663_1 (TYROSINE-PROTEIN KINASE BTK)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	9 / 12	VAL A 416 ALA A 428 LYS A 430 VAL A 458 THR A 474 TYR A 476 GLY A 480 GLU A 488 LEU A 528	None	0.86A	3octA-1k2pA: 14.5	3octA-1k2pA: 99.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OCT_A_1N1A663_1 (TYROSINE-PROTEIN KINASE BTK)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	VAL A 416 LYS A 430 MET A 449 VAL A 458 THR A 474 GLY A 480 GLU A 488 LEU A 528	None	1.08A	3octA-1k2pA: 14.5	3octA-1k2pA: 99.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 12	VAL A 416 ALA A 428 LYS A 430 THR A 474 PHE A 540 GLY A 541	None	0.87A	3og7A-1k2pA: 22.7	3og7A-1k2pA: 29.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXZ_A_0LIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 12	ALA A 428 LEU A 457 VAL A 458 THR A 474 GLY A 480 HIS A 519	None	0.69A	3oxzA-1k2pA: 28.6	3oxzA-1k2pA: 45.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXZ_A_0LIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	5 / 9	LEU A 408 LYS A 430 ILE A 472 LEU A 528 VAL A 537	None	1.00A	3oxzA-1k2pA: 28.6	3oxzA-1k2pA: 45.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3QLG_B_1N1B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	ALA A 428 VAL A 458 THR A 474 TYR A 476 GLY A 480 LEU A 528 ASP A 539	None	0.48A	3qlgB-1k2pA: 26.4	3qlgB-1k2pA: 38.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3QLG_B_1N1B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	VAL A 416 ALA A 428 VAL A 458 TYR A 476 GLY A 480 LEU A 528 ASP A 539	None	0.57A	3qlgB-1k2pA: 26.4	3qlgB-1k2pA: 38.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_A_1N1A1_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	VAL A 416 ALA A 428 VAL A 458 ILE A 472 TYR A 476 GLY A 480 LEU A 528	None	0.51A	3sxrA-1k2pA: 32.7	3sxrA-1k2pA: 65.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_B_1N1B2_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	LEU A 408 VAL A 416 VAL A 458 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.83A	3sxrB-1k2pA: 32.7	3sxrB-1k2pA: 65.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_B_1N1B2_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	VAL A 416 ALA A 428 VAL A 458 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.66A	3sxrB-1k2pA: 32.7	3sxrB-1k2pA: 65.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UE4_A_DB8A601_1 (TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	ALA A 428 LYS A 430 VAL A 458 ILE A 472 THR A 474 MET A 477 GLY A 480 LEU A 528	None	0.58A	3ue4A-1k2pA: 32.0	3ue4A-1k2pA: 45.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UE4_B_DB8B601_1 (TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	VAL A 416 ALA A 428 VAL A 458 ILE A 472 THR A 474 GLY A 480 LEU A 528	None	0.76A	3ue4B-1k2pA: 31.7	3ue4B-1k2pA: 45.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3V5W_A_8PRA701_1 (G-PROTEIN COUPLED RECEPTOR KINASE 2)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	GLY A 414 VAL A 416 ALA A 428 VAL A 458 LEU A 528 SER A 538 ASP A 539	None	1.02A	3v5wA-1k2pA: 8.3	3v5wA-1k2pA: 16.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3WZD_A_LEVA1201_2 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 5	LYS A 430 VAL A 458 LEU A 528 ASP A 539	None	0.92A	3wzdA-1k2pA: 27.8	3wzdA-1k2pA: 34.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	LEU A 408 VAL A 416 ALA A 428 LYS A 430 VAL A 458 GLY A 480 LEU A 528	None	0.76A	4ag8A-1k2pA: 27.4	4ag8A-1k2pA: 33.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4BKJ_B_STIB1000_2 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 5	LYS A 430 LEU A 452 TYR A 476 MET A 477	None	1.28A	4bkjB-1k2pA: 23.4	4bkjB-1k2pA: 29.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4CCQ_A_ACTA1317_0 (THIOREDOXIN REDUCTASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	3 / 3	LEU A 569 GLU A 567 SER A 572	None	0.82A	4ccqA-1k2pA: undetectable	4ccqA-1k2pA: 23.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4CKI_A_ADNA2022_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 11	GLY A 411 VAL A 416 ALA A 428 TYR A 476 GLY A 480 LEU A 528	None	0.66A	4ckiA-1k2pA: 28.1	4ckiA-1k2pA: 35.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4CKI_A_ADNA2022_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 11	LEU A 408 GLY A 411 VAL A 416 TYR A 476 GLY A 480 LEU A 528	None	0.88A	4ckiA-1k2pA: 28.1	4ckiA-1k2pA: 35.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4DC3_A_ADNA401_2 (ADENOSINE KINASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 4	LEU A 542 ILE A 432 GLY A 541 PHE A 442	None	1.08A	4dc3A-1k2pA: undetectable	4dc3A-1k2pA: 21.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4E1V_A_URFA1301_1 (URIDINE PHOSPHORYLASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 8	THR A 474 GLY A 462 ILE A 472 VAL A 463	None	0.79A	4e1vA-1k2pA: undetectable	4e1vA-1k2pA: 19.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4E1V_C_URFC1301_1 (URIDINE PHOSPHORYLASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 8	THR A 474 GLY A 462 ILE A 472 VAL A 463	None	0.79A	4e1vC-1k2pA: undetectable	4e1vC-1k2pA: 19.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4E1V_D_URFD1301_1 (URIDINE PHOSPHORYLASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 8	THR A 474 GLY A 462 ILE A 472 VAL A 463	None	0.77A	4e1vD-1k2pA: undetectable	4e1vD-1k2pA: 19.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4E1V_E_URFE1301_1 (URIDINE PHOSPHORYLASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 8	THR A 474 GLY A 462 ILE A 472 VAL A 463	None	0.80A	4e1vE-1k2pA: undetectable	4e1vE-1k2pA: 19.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4E1V_G_URFG1301_1 (URIDINE PHOSPHORYLASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 8	THR A 474 GLY A 462 ILE A 472 VAL A 463	None	0.90A	4e1vG-1k2pA: undetectable	4e1vG-1k2pA: 19.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4E1V_H_URFH1301_1 (URIDINE PHOSPHORYLASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 8	THR A 474 GLY A 462 ILE A 472 VAL A 463	None	0.83A	4e1vH-1k2pA: undetectable	4e1vH-1k2pA: 19.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4HJO_A_AQ4A1001_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	ALA A 428 LYS A 430 THR A 474 MET A 477 GLY A 480 LEU A 528 ASP A 539	None	0.96A	4hjoA-1k2pA: 30.0	4hjoA-1k2pA: 32.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4HJO_A_AQ4A1001_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	ALA A 428 THR A 474 MET A 477 GLY A 480 CYH A 481 LEU A 528 ASP A 539	None	0.68A	4hjoA-1k2pA: 30.0	4hjoA-1k2pA: 32.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4HJO_A_AQ4A1001_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	LEU A 408 VAL A 416 LYS A 430 MET A 477 GLY A 480 LEU A 528 ASP A 539	None	1.10A	4hjoA-1k2pA: 30.0	4hjoA-1k2pA: 32.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4HJO_A_AQ4A1001_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	LEU A 408 VAL A 416 MET A 477 GLY A 480 CYH A 481 LEU A 528 ASP A 539	None	0.97A	4hjoA-1k2pA: 30.0	4hjoA-1k2pA: 32.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4HJO_A_AQ4A1001_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	VAL A 416 ALA A 428 LYS A 430 MET A 477 GLY A 480 LEU A 528 ASP A 539	None	0.99A	4hjoA-1k2pA: 30.0	4hjoA-1k2pA: 32.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4HJO_A_AQ4A1001_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	VAL A 416 ALA A 428 MET A 477 GLY A 480 CYH A 481 LEU A 528 ASP A 539	None	0.87A	4hjoA-1k2pA: 30.0	4hjoA-1k2pA: 32.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4KS8_A_B49A701_1 (SERINE/THREONINE-PRO TEIN KINASE PAK 6)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 10	ALA A 428 VAL A 458 GLY A 480 LEU A 528 SER A 538 ASP A 539	None	0.84A	4ks8A-1k2pA: 20.8	4ks8A-1k2pA: 27.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4L9I_A_8PRA601_1 (RHODOPSIN KINASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 7	VAL A 416 ALA A 428 MET A 477 LEU A 528	None	0.67A	4l9iA-1k2pA: 10.0	4l9iA-1k2pA: 21.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4L9I_B_8PRB601_1 (RHODOPSIN KINASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	5 / 8	VAL A 416 ALA A 428 LYS A 430 MET A 477 LEU A 528	None	0.72A	4l9iB-1k2pA: 21.8	4l9iB-1k2pA: 21.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXO_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	ALA A 428 LYS A 430 VAL A 458 ILE A 472 THR A 474 TYR A 476 GLY A 480	None	0.65A	4mxoA-1k2pA: 26.7	4mxoA-1k2pA: 38.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXO_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	ALA A 428 LYS A 430 VAL A 458 ILE A 472 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.65A	4mxoB-1k2pA: 26.6	4mxoB-1k2pA: 38.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXO_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	9 / 12	VAL A 416 ALA A 428 LYS A 430 VAL A 458 ILE A 472 TYR A 476 GLY A 480 LEU A 528 ASP A 539	None	0.88A	4mxoB-1k2pA: 26.6	4mxoB-1k2pA: 38.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXX_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	ALA A 428 LYS A 430 VAL A 458 ILE A 472 TYR A 476 GLY A 480 LEU A 528	None	0.62A	4mxxA-1k2pA: 26.7	4mxxA-1k2pA: 38.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXX_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	ALA A 428 LYS A 430 VAL A 458 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.59A	4mxxA-1k2pA: 26.7	4mxxA-1k2pA: 38.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXX_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	ALA A 428 LYS A 430 VAL A 458 THR A 474 TYR A 476 MET A 477 GLY A 480 LEU A 528	None	0.65A	4mxxB-1k2pA: 24.9	4mxxB-1k2pA: 38.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXX_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	VAL A 416 ALA A 428 LYS A 430 VAL A 458 TYR A 476 MET A 477 GLY A 480 LEU A 528	None	0.81A	4mxxB-1k2pA: 24.9	4mxxB-1k2pA: 38.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXY_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	VAL A 416 ALA A 428 LYS A 430 VAL A 458 ILE A 472 TYR A 476 GLY A 480 LEU A 528	None	0.69A	4mxyA-1k2pA: 25.8	4mxyA-1k2pA: 37.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXZ_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	VAL A 416 ALA A 428 LYS A 430 VAL A 458 ILE A 472 TYR A 476 GLY A 480 LEU A 528	None	0.69A	4mxzA-1k2pA: 25.8	4mxzA-1k2pA: 37.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4O0S_A_ADNA500_1 (AURORA KINASE A)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 11	LEU A 408 VAL A 416 ALA A 428 LYS A 430 ASN A 526 LEU A 528 ASP A 539	None	0.68A	4o0sA-1k2pA: 15.4	4o0sA-1k2pA: 25.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OTW_A_DB8A1101_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	VAL A 416 LYS A 430 VAL A 458 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.92A	4otwA-1k2pA: 29.0	4otwA-1k2pA: 28.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4PCU_B_SAMB603_0 (CYSTATHIONINE BETA-SYNTHASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	5 / 9	PHE A 540 ASP A 539 VAL A 458 THR A 474 ILE A 472	None	1.45A	4pcuA-1k2pA: undetectable 4pcuB-1k2pA: 0.0	4pcuA-1k2pA: 18.77 4pcuB-1k2pA: 18.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4QRC_A_0LIA802_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	5 / 8	LEU A 408 VAL A 416 LYS A 430 HIS A 519 LEU A 528	None	1.08A	4qrcA-1k2pA: 27.9	4qrcA-1k2pA: 33.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 12	ALA A 428 LYS A 430 ILE A 472 THR A 474 PHE A 540 GLY A 541	None	0.63A	4rzvA-1k2pA: 8.1	4rzvA-1k2pA: 30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 12	VAL A 416 ALA A 428 LYS A 430 THR A 474 PHE A 540 GLY A 541	None	0.80A	4rzvB-1k2pA: 28.2	4rzvB-1k2pA: 30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U0I_A_0LIA1001_2 (MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 12	ALA A 428 LYS A 430 THR A 474 GLY A 480 HIS A 519 LEU A 528	None	0.64A	4u0iA-1k2pA: 27.5	4u0iA-1k2pA: 33.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4UDA_A_DEXA1985_2 (MINERALOCORTICOID RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 6	LEU A 483 LEU A 593 PHE A 493 VAL A 529	None	0.99A	4udaA-1k2pA: 0.0	4udaA-1k2pA: 22.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_A_AXIA9000_1 (TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 11	ALA A 428 THR A 474 MET A 477 GLY A 480 ASN A 526 LEU A 528	None	0.46A	4wa9A-1k2pA: 29.8	4wa9A-1k2pA: 45.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_B_AXIB9000_1 (TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	VAL A 416 ALA A 428 LYS A 430 THR A 474 MET A 477 GLY A 480 LEU A 528	None	0.79A	4wa9B-1k2pA: 31.4	4wa9B-1k2pA: 45.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_B_AXIB9000_1 (TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	VAL A 416 ALA A 428 THR A 474 MET A 477 GLY A 480 ASN A 526 LEU A 528	None	0.81A	4wa9B-1k2pA: 31.4	4wa9B-1k2pA: 45.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XEY_A_1N1A601_1 (TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	ALA A 428 LYS A 430 VAL A 458 ILE A 472 THR A 474 GLY A 480 LEU A 528	None	0.69A	4xeyA-1k2pA: 31.9	4xeyA-1k2pA: 35.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XEY_A_1N1A601_1 (TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	VAL A 416 ALA A 428 LYS A 430 VAL A 458 ILE A 472 GLY A 480 LEU A 528	None	0.76A	4xeyA-1k2pA: 31.9	4xeyA-1k2pA: 35.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XLI_A_1N1A601_1 (NON-SPECIFIC PROTEIN-TYROSINE KINASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	ALA A 428 LYS A 430 VAL A 458 TYR A 476 MET A 477 GLY A 480 LEU A 528	None	0.64A	4xliA-1k2pA: 32.0	4xliA-1k2pA: 44.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XLI_A_1N1A601_1 (NON-SPECIFIC PROTEIN-TYROSINE KINASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	ALA A 428 VAL A 458 THR A 474 TYR A 476 MET A 477 GLY A 480 LEU A 528	None	0.50A	4xliA-1k2pA: 32.0	4xliA-1k2pA: 44.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XLI_B_1N1B600_1 (NON-SPECIFIC PROTEIN-TYROSINE KINASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	ALA A 428 LYS A 430 VAL A 458 ILE A 472 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.55A	4xliB-1k2pA: 27.8	4xliB-1k2pA: 44.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4YSH_B_GLYB402_0 (GLYCINE OXIDASE)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 5	MET A 449 GLU A 445 ARG A 520 ARG A 544	None	1.31A	4yshB-1k2pA: undetectable	4yshB-1k2pA: 21.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ZAU_A_YY3A1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	5 / 8	VAL A 416 ALA A 428 MET A 477 GLY A 480 CYH A 481	None	0.54A	4zauA-1k2pA: 29.8	4zauA-1k2pA: 33.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_A_032A401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 12	ALA A 428 ILE A 472 THR A 474 TYR A 476 PHE A 540 GLY A 541	None	0.80A	5hesA-1k2pA: 10.0	5hesA-1k2pA: 29.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_A_032A401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 12	VAL A 416 ALA A 428 ILE A 472 TYR A 476 PHE A 540 GLY A 541	None	0.73A	5hesA-1k2pA: 10.0	5hesA-1k2pA: 29.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_B_032B401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	VAL A 416 ALA A 428 LYS A 430 ILE A 472 THR A 474 TYR A 476 PHE A 540 GLY A 541	None	0.78A	5hesB-1k2pA: 21.2	5hesB-1k2pA: 29.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	5 / 12	GLY A 411 VAL A 416 ALA A 428 LYS A 430 ILE A 472	None	0.88A	5hieB-1k2pA: 25.7	5hieB-1k2pA: 29.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	5 / 12	VAL A 416 ALA A 428 LYS A 430 ILE A 472 THR A 474	None	0.83A	5hieD-1k2pA: 25.9	5hieD-1k2pA: 29.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5I9X_A_DB8A1001_1 (EPHRIN TYPE-A RECEPTOR 2)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	ALA A 428 ILE A 472 THR A 474 TYR A 476 GLY A 480 GLU A 488 LEU A 528 SER A 538	None	1.06A	5i9xA-1k2pA: 28.7	5i9xA-1k2pA: 39.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5I9X_A_DB8A1001_1 (EPHRIN TYPE-A RECEPTOR 2)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	ALA A 428 LYS A 430 ILE A 472 TYR A 476 GLY A 480 GLU A 488 LEU A 528 SER A 538	None	1.11A	5i9xA-1k2pA: 28.7	5i9xA-1k2pA: 39.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5I9Y_A_1N1A1001_1 (EPHRIN TYPE-A RECEPTOR 2)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	ALA A 428 LYS A 430 THR A 474 TYR A 476 GLY A 480 GLU A 488 LEU A 528	None	1.13A	5i9yA-1k2pA: 24.4	5i9yA-1k2pA: 39.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5I9Y_A_1N1A1001_1 (EPHRIN TYPE-A RECEPTOR 2)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	ALA A 428 THR A 474 TYR A 476 GLY A 480 GLU A 488 LEU A 528 SER A 538	None	1.06A	5i9yA-1k2pA: 24.4	5i9yA-1k2pA: 39.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MO4_A_NILA601_2 (TYROSINE-PROTEIN KINASE ABL1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 12	ALA A 428 LEU A 457 VAL A 458 PHE A 517 HIS A 519 LEU A 528	None	0.62A	5mo4A-1k2pA: 24.8	5mo4A-1k2pA: 28.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	ALA A 428 MET A 449 ILE A 472 THR A 474 GLY A 480 ASN A 484 LEU A 528 PHE A 540	None	1.16A	5p9iA-1k2pA: 33.6	5p9iA-1k2pA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	ALA A 428 MET A 449 THR A 474 GLY A 480 ASN A 484 LEU A 528 SER A 538 PHE A 540	None	1.06A	5p9iA-1k2pA: 33.6	5p9iA-1k2pA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	GLY A 414 VAL A 416 ALA A 428 LYS A 430 ILE A 472 THR A 474 PHE A 540	None	1.17A	5p9iA-1k2pA: 33.6	5p9iA-1k2pA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	VAL A 416 ALA A 428 ILE A 472 THR A 474 GLY A 480 ASN A 484 LEU A 528 PHE A 540	None	1.25A	5p9iA-1k2pA: 33.6	5p9iA-1k2pA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	VAL A 416 ALA A 428 THR A 474 GLY A 480 ASN A 484 LEU A 528 SER A 538 PHE A 540	None	1.13A	5p9iA-1k2pA: 33.6	5p9iA-1k2pA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5P9I_A_1E8A701_2 (TYROSINE-PROTEIN KINASE BTK)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 5	LEU A 408 TYR A 476 MET A 477 CYH A 481	None	1.03A	5p9iA-1k2pA: 33.6	5p9iA-1k2pA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5P9I_A_1E8A701_2 (TYROSINE-PROTEIN KINASE BTK)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 5	TYR A 476 MET A 477 CYH A 481 ASP A 539	None	0.54A	5p9iA-1k2pA: 33.6	5p9iA-1k2pA: 100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_C_1E8C1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	6 / 12	VAL A 416 ALA A 428 MET A 449 GLY A 480 CYH A 481 ASP A 539	None	0.89A	5yu9C-1k2pA: 28.4	5yu9C-1k2pA: 14.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_D_1E8D1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	7 / 12	VAL A 416 ALA A 428 MET A 449 GLY A 480 CYH A 481 LEU A 528 ASP A 539	None	0.83A	5yu9D-1k2pA: 28.8	5yu9D-1k2pA: 14.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZMQ_I_PACI1_0 (SERINE PROTEASE NS3 SERINE PROTEASE SUBUNIT NS2B PEPTIDE PAC-DLY-DLY-DAR)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	3 / 3	VAL A 448 TYR A 545 GLU A 444	None	0.94A	5zmqD-1k2pA: undetectable 5zmqE-1k2pA: undetectable	5zmqD-1k2pA: 20.40 5zmqE-1k2pA: 16.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6BSD_A_1N1A901_0 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	VAL A 416 ALA A 428 LYS A 430 THR A 474 TYR A 476 MET A 477 GLY A 480 LEU A 528	None	0.69A	6bsdA-1k2pA: 23.4	6bsdA-1k2pA: 15.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6E43_A_BEZA502_0 (INDOLEAMINE 2,3-DIOXYGENASE 1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 6	LEU A 483 LEU A 486 ARG A 487 HIS A 491	None	1.01A	6e43A-1k2pA: 0.0	6e43A-1k2pA: 22.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6E43_B_BEZB502_0 (INDOLEAMINE 2,3-DIOXYGENASE 1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 6	LEU A 483 LEU A 486 ARG A 487 HIS A 491	None	1.03A	6e43B-1k2pA: 0.0	6e43B-1k2pA: 22.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6E43_C_BEZC502_0 (INDOLEAMINE 2,3-DIOXYGENASE 1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 6	LEU A 483 LEU A 486 ARG A 487 HIS A 491	None	1.01A	6e43C-1k2pA: 0.0	6e43C-1k2pA: 22.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6E43_D_BEZD502_0 (INDOLEAMINE 2,3-DIOXYGENASE 1)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	4 / 6	LEU A 483 LEU A 486 ARG A 487 HIS A 491	None	0.99A	6e43D-1k2pA: 0.0	6e43D-1k2pA: 22.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6FNM_A_1N1A1001_1 (-)	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	8 / 12	ALA A 428 LYS A 430 ILE A 472 THR A 474 MET A 477 GLY A 480 LEU A 528 SER A 538	None	0.76A	6fnmA-1k2pA: 26.0	6fnmA-1k2pA: 36.58

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1ICU_C_NIOC225_1","OXYGEN-INSENSITIVE NAD(P)H NITROREDUCTASE;OXYGEN-INSENSITIVE NAD(P)H NITROREDUCTASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"SER A 578;PHE A 574;PHE A 559;GLU A 567","None","1.08A","1icuC-1k2pA:0.0;1icuD-1k2pA:0.0","1icuC-1k2pA:20.36;1icuD-1k2pA:20.36"],["1JLF_A_NVPA999_1","HIV-1 RT A-CHAIN;HIV-1 RT B-CHAIN","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"LEU A 486;VAL A 529;CYH A 527;GLY A 480","None","0.99A","1jlfA-1k2pA:undetectable;1jlfB-1k2pA:1.0","1jlfA-1k2pA:18.05;1jlfB-1k2pA:19.95"],["1M17_A_AQ4A999_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"ALA A 428;LYS A 430;THR A 474;MET A 477;GLY A 480;LEU A 528;ASP A 539","None","0.57A","1m17A-1k2pA:30.0","1m17A-1k2pA:32.71"],["1MXD_A_ACRA733_1","ALPHA AMYLASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"SER A 553;THR A 552;LEU A 547;ASP A 548","None","1.23A","1mxdA-1k2pA:undetectable","1mxdA-1k2pA:18.83"],["1RXC_B_URFB2011_1","URIDINE PHOSPHORYLASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"THR A 474;GLY A 462;ILE A 472;VAL A 463","None","0.72A","1rxcB-1k2pA:undetectable","1rxcB-1k2pA:19.85"],["1RXC_E_URFE2031_1","URIDINE PHOSPHORYLASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"THR A 474;GLY A 462;ILE A 472;VAL A 463","None","0.79A","1rxcE-1k2pA:undetectable","1rxcE-1k2pA:19.85"],["1RXC_I_URFI2041_1","URIDINE PHOSPHORYLASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"THR A 474;GLY A 462;ILE A 472;VAL A 463","None","0.78A","1rxcI-1k2pA:undetectable","1rxcI-1k2pA:19.85"],["1RXC_K_URFK2061_1","URIDINE PHOSPHORYLASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"THR A 474;GLY A 462;ILE A 472;VAL A 463","None","0.70A","1rxcK-1k2pA:undetectable","1rxcK-1k2pA:19.85"],["1XF1_A_ACTA1107_0","C5A PEPTIDASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"LEU A 402;GLY A 419;ILE A 473;PHE A 471","None","0.91A","1xf1A-1k2pA:undetectable","1xf1A-1k2pA:16.11"],["1XKK_A_FMMA91_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"ALA A 428;MET A 449;THR A 474;GLY A 480;CYH A 481;ASP A 539;PHE A 540","None","1.03A","1xkkA-1k2pA:29.5","1xkkA-1k2pA:31.47"],["1XKK_A_FMMA91_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",9,"ALA A 428;THR A 474;GLY A 480;CYH A 481;LEU A 483;ARG A 487;LEU A 528;ASP A 539;PHE A 540","None","0.91A","1xkkA-1k2pA:29.5","1xkkA-1k2pA:31.47"],["2HYY_A_STIA600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"LEU A 408;LYS A 430;VAL A 458;ILE A 472","None","0.88A","2hyyA-1k2pA:29.4","2hyyA-1k2pA:45.99"],["2W3B_B_FOLB401_1","DIHYDROFOLATE REDUCTASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",3,"GLU A 441;GLN A 467;ARG A 468","None","0.81A","2w3bB-1k2pA:undetectable","2w3bB-1k2pA:22.13"],["2Y6O_A_1N1A1892_1","EPHRIN TYPE-A RECEPTOR 4","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"ALA A 428;LYS A 430;ILE A 472;THR A 474;TYR A 476;GLY A 480;LEU A 528;SER A 538","None","0.72A","2y6oA-1k2pA:26.5","2y6oA-1k2pA:39.86"],["2Y7J_A_B49A1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"VAL A 416;ALA A 428;MET A 477;GLY A 480;LEU A 528;ASP A 539","None","0.54A","2y7jA-1k2pA:19.3","2y7jA-1k2pA:22.65"],["2Y7J_B_B49B1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"VAL A 416;ALA A 428;MET A 477;GLY A 480;LEU A 528;ASP A 539","None","0.55A","2y7jB-1k2pA:19.9","2y7jB-1k2pA:22.65"],["2YFX_A_VGHA9000_1","TYROSINE-PROTEIN KINASE RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"ALA A 428;MET A 477;GLY A 480;LEU A 528","None","0.19A","2yfxA-1k2pA:28.8","2yfxA-1k2pA:34.85"],["2ZVA_A_1N1A513_1","TYROSINE-PROTEIN KINASE LYN","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"ALA A 428;LYS A 430;VAL A 458;ILE A 472;THR A 474;MET A 477;GLY A 480;LEU A 528","None","0.50A","2zvaA-1k2pA:27.8","2zvaA-1k2pA:41.67"],["3AOX_A_EMHA901_1","ALK TYROSINE KINASE RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"ALA A 428;LYS A 430;VAL A 458;MET A 477;GLY A 480;LEU A 528","None","0.53A","3aoxA-1k2pA:28.3","3aoxA-1k2pA:33.72"],["3BBT_B_FMMB91_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"ALA A 428;LEU A 460;THR A 474;GLY A 480;LEU A 528;ASP A 539;PHE A 540","None","0.74A","3bbtB-1k2pA:29.3","3bbtB-1k2pA:34.78"],["3BBT_B_FMMB91_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"VAL A 416;ALA A 428;MET A 449;LEU A 460;GLY A 480;LEU A 528;ASP A 539;PHE A 540","None","0.74A","3bbtB-1k2pA:29.3","3bbtB-1k2pA:34.78"],["3CS9_A_NILA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"LEU A 408;VAL A 416;LYS A 430;VAL A 458;ILE A 472;VAL A 537","None","0.91A","3cs9A-1k2pA:25.6","3cs9A-1k2pA:45.68"],["3CS9_A_NILA600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"ALA A 428;LEU A 457;THR A 474;GLY A 480;PHE A 517;HIS A 519;LEU A 528","None","0.66A","3cs9A-1k2pA:25.6","3cs9A-1k2pA:45.68"],["3CS9_B_NILB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"LEU A 408;VAL A 416;LYS A 430;VAL A 458;ILE A 472;LEU A 528;VAL A 537","None","1.04A","3cs9B-1k2pA:29.0","3cs9B-1k2pA:45.68"],["3CS9_C_NILC600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",5,"ALA A 428;LEU A 457;THR A 474;PHE A 517;HIS A 519","None","0.78A","3cs9C-1k2pA:28.9","3cs9C-1k2pA:45.68"],["3CS9_C_NILC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"LEU A 408;VAL A 416;LYS A 430;VAL A 458;ILE A 472;VAL A 537","None","0.89A","3cs9C-1k2pA:28.9","3cs9C-1k2pA:45.68"],["3CS9_D_NILD600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"ALA A 428;LEU A 457;THR A 474;GLY A 480;PHE A 517;HIS A 519","None","0.59A","3cs9D-1k2pA:25.6","3cs9D-1k2pA:45.68"],["3G0E_A_B49A9000_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.78A","3g0eA-1k2pA:26.6","3g0eA-1k2pA:34.87"],["3G0F_A_B49A9001_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"VAL A 416;ALA A 428;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.74A","3g0fA-1k2pA:24.1","3g0fA-1k2pA:34.87"],["3G0F_B_B49B9001_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"VAL A 416;ALA A 428;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.64A","3g0fB-1k2pA:27.2","3g0fB-1k2pA:34.87"],["3G5D_A_1N1A1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"VAL A 416;ALA A 428;VAL A 458;ILE A 472;TYR A 476;GLY A 480;LEU A 528","None","0.53A","3g5dA-1k2pA:26.5","3g5dA-1k2pA:39.02"],["3G5D_B_1N1B1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"VAL A 416;ALA A 428;LYS A 430;VAL A 458;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.63A","3g5dB-1k2pA:26.5","3g5dB-1k2pA:39.02"],["3K54_A_1N1A1_1","TYROSINE-PROTEIN KINASE BTK","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",9,"ALA A 428;LYS A 430;VAL A 458;ILE A 472;THR A 474;TYR A 476;GLY A 480;LEU A 528;SER A 538","None","0.64A","3k54A-1k2pA:29.4","3k54A-1k2pA:99.62"],["3K5V_B_STIB2_2","TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"LEU A 408;LYS A 430;VAL A 458;ILE A 472","None","0.90A","3k5vB-1k2pA:28.4","3k5vB-1k2pA:44.98"],["3LXK_A_MI1A1125_1","TYROSINE-PROTEIN KINASE JAK3","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"LEU A 408;VAL A 416;ALA A 428;LYS A 430;VAL A 458;TYR A 476;CYH A 481","None","0.80A","3lxkA-1k2pA:30.3","3lxkA-1k2pA:29.88"],["3MIY_A_B49A1_1","TYROSINE-PROTEIN KINASE ITK\/TSK","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"ALA A 428;LYS A 430;MET A 477;GLY A 480;LEU A 528;ASP A 539","None","0.76A","3miyA-1k2pA:26.8","3miyA-1k2pA:57.41"],["3MIY_A_B49A1_1","TYROSINE-PROTEIN KINASE ITK\/TSK","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"ALA A 428;VAL A 458;MET A 477;GLY A 480;LEU A 528;SER A 538;ASP A 539","None","0.83A","3miyA-1k2pA:26.8","3miyA-1k2pA:57.41"],["3MSS_D_STID1_2","TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"VAL A 416;LYS A 430;VAL A 458;ILE A 472","None","0.78A","3mssD-1k2pA:28.9","3mssD-1k2pA:44.98"],["3OCT_A_1N1A663_1","TYROSINE-PROTEIN KINASE BTK","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"LEU A 408;VAL A 416;LYS A 430;MET A 449;VAL A 458;GLY A 480;GLU A 488;LEU A 528","None","1.10A","3octA-1k2pA:14.5","3octA-1k2pA:99.62"],["3OCT_A_1N1A663_1","TYROSINE-PROTEIN KINASE BTK","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"LEU A 408;VAL A 416;LYS A 430;VAL A 458;TYR A 476;GLY A 480;GLU A 488;LEU A 528","None","0.93A","3octA-1k2pA:14.5","3octA-1k2pA:99.62"],["3OCT_A_1N1A663_1","TYROSINE-PROTEIN KINASE BTK","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",9,"VAL A 416;ALA A 428;LYS A 430;VAL A 458;THR A 474;TYR A 476;GLY A 480;GLU A 488;LEU A 528","None","0.86A","3octA-1k2pA:14.5","3octA-1k2pA:99.62"],["3OCT_A_1N1A663_1","TYROSINE-PROTEIN KINASE BTK","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"VAL A 416;LYS A 430;MET A 449;VAL A 458;THR A 474;GLY A 480;GLU A 488;LEU A 528","None","1.08A","3octA-1k2pA:14.5","3octA-1k2pA:99.62"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"VAL A 416;ALA A 428;LYS A 430;THR A 474;PHE A 540;GLY A 541","None","0.87A","3og7A-1k2pA:22.7","3og7A-1k2pA:29.22"],["3OXZ_A_0LIA1_1","TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"ALA A 428;LEU A 457;VAL A 458;THR A 474;GLY A 480;HIS A 519","None","0.69A","3oxzA-1k2pA:28.6","3oxzA-1k2pA:45.42"],["3OXZ_A_0LIA1_2","TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",5,"LEU A 408;LYS A 430;ILE A 472;LEU A 528;VAL A 537","None","1.00A","3oxzA-1k2pA:28.6","3oxzA-1k2pA:45.42"],["3QLG_B_1N1B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"ALA A 428;VAL A 458;THR A 474;TYR A 476;GLY A 480;LEU A 528;ASP A 539","None","0.48A","3qlgB-1k2pA:26.4","3qlgB-1k2pA:38.33"],["3QLG_B_1N1B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"VAL A 416;ALA A 428;VAL A 458;TYR A 476;GLY A 480;LEU A 528;ASP A 539","None","0.57A","3qlgB-1k2pA:26.4","3qlgB-1k2pA:38.33"],["3SXR_A_1N1A1_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"VAL A 416;ALA A 428;VAL A 458;ILE A 472;TYR A 476;GLY A 480;LEU A 528","None","0.51A","3sxrA-1k2pA:32.7","3sxrA-1k2pA:65.67"],["3SXR_B_1N1B2_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"LEU A 408;VAL A 416;VAL A 458;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.83A","3sxrB-1k2pA:32.7","3sxrB-1k2pA:65.67"],["3SXR_B_1N1B2_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"VAL A 416;ALA A 428;VAL A 458;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.66A","3sxrB-1k2pA:32.7","3sxrB-1k2pA:65.67"],["3UE4_A_DB8A601_1","TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"ALA A 428;LYS A 430;VAL A 458;ILE A 472;THR A 474;MET A 477;GLY A 480;LEU A 528","None","0.58A","3ue4A-1k2pA:32.0","3ue4A-1k2pA:45.10"],["3UE4_B_DB8B601_1","TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"VAL A 416;ALA A 428;VAL A 458;ILE A 472;THR A 474;GLY A 480;LEU A 528","None","0.76A","3ue4B-1k2pA:31.7","3ue4B-1k2pA:45.10"],["3V5W_A_8PRA701_1","G-PROTEIN COUPLED RECEPTOR KINASE 2","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"GLY A 414;VAL A 416;ALA A 428;VAL A 458;LEU A 528;SER A 538;ASP A 539","None","1.02A","3v5wA-1k2pA:8.3","3v5wA-1k2pA:16.96"],["3WZD_A_LEVA1201_2","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"LYS A 430;VAL A 458;LEU A 528;ASP A 539","None","0.92A","3wzdA-1k2pA:27.8","3wzdA-1k2pA:34.09"],["4AG8_A_AXIA2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"LEU A 408;VAL A 416;ALA A 428;LYS A 430;VAL A 458;GLY A 480;LEU A 528","None","0.76A","4ag8A-1k2pA:27.4","4ag8A-1k2pA:33.54"],["4BKJ_B_STIB1000_2","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"LYS A 430;LEU A 452;TYR A 476;MET A 477","None","1.28A","4bkjB-1k2pA:23.4","4bkjB-1k2pA:29.84"],["4CCQ_A_ACTA1317_0","THIOREDOXIN REDUCTASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",3,"LEU A 569;GLU A 567;SER A 572","None","0.82A","4ccqA-1k2pA:undetectable","4ccqA-1k2pA:23.72"],["4CKI_A_ADNA2022_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"GLY A 411;VAL A 416;ALA A 428;TYR A 476;GLY A 480;LEU A 528","None","0.66A","4ckiA-1k2pA:28.1","4ckiA-1k2pA:35.06"],["4CKI_A_ADNA2022_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"LEU A 408;GLY A 411;VAL A 416;TYR A 476;GLY A 480;LEU A 528","None","0.88A","4ckiA-1k2pA:28.1","4ckiA-1k2pA:35.06"],["4DC3_A_ADNA401_2","ADENOSINE KINASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"LEU A 542;ILE A 432;GLY A 541;PHE A 442","None","1.08A","4dc3A-1k2pA:undetectable","4dc3A-1k2pA:21.26"],["4E1V_A_URFA1301_1","URIDINE PHOSPHORYLASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"THR A 474;GLY A 462;ILE A 472;VAL A 463","None","0.79A","4e1vA-1k2pA:undetectable","4e1vA-1k2pA:19.85"],["4E1V_C_URFC1301_1","URIDINE PHOSPHORYLASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"THR A 474;GLY A 462;ILE A 472;VAL A 463","None","0.79A","4e1vC-1k2pA:undetectable","4e1vC-1k2pA:19.85"],["4E1V_D_URFD1301_1","URIDINE PHOSPHORYLASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"THR A 474;GLY A 462;ILE A 472;VAL A 463","None","0.77A","4e1vD-1k2pA:undetectable","4e1vD-1k2pA:19.85"],["4E1V_E_URFE1301_1","URIDINE PHOSPHORYLASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"THR A 474;GLY A 462;ILE A 472;VAL A 463","None","0.80A","4e1vE-1k2pA:undetectable","4e1vE-1k2pA:19.85"],["4E1V_G_URFG1301_1","URIDINE PHOSPHORYLASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"THR A 474;GLY A 462;ILE A 472;VAL A 463","None","0.90A","4e1vG-1k2pA:undetectable","4e1vG-1k2pA:19.85"],["4E1V_H_URFH1301_1","URIDINE PHOSPHORYLASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"THR A 474;GLY A 462;ILE A 472;VAL A 463","None","0.83A","4e1vH-1k2pA:undetectable","4e1vH-1k2pA:19.85"],["4HJO_A_AQ4A1001_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"ALA A 428;LYS A 430;THR A 474;MET A 477;GLY A 480;LEU A 528;ASP A 539","None","0.96A","4hjoA-1k2pA:30.0","4hjoA-1k2pA:32.31"],["4HJO_A_AQ4A1001_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"ALA A 428;THR A 474;MET A 477;GLY A 480;CYH A 481;LEU A 528;ASP A 539","None","0.68A","4hjoA-1k2pA:30.0","4hjoA-1k2pA:32.31"],["4HJO_A_AQ4A1001_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"LEU A 408;VAL A 416;LYS A 430;MET A 477;GLY A 480;LEU A 528;ASP A 539","None","1.10A","4hjoA-1k2pA:30.0","4hjoA-1k2pA:32.31"],["4HJO_A_AQ4A1001_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"LEU A 408;VAL A 416;MET A 477;GLY A 480;CYH A 481;LEU A 528;ASP A 539","None","0.97A","4hjoA-1k2pA:30.0","4hjoA-1k2pA:32.31"],["4HJO_A_AQ4A1001_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"VAL A 416;ALA A 428;LYS A 430;MET A 477;GLY A 480;LEU A 528;ASP A 539","None","0.99A","4hjoA-1k2pA:30.0","4hjoA-1k2pA:32.31"],["4HJO_A_AQ4A1001_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"VAL A 416;ALA A 428;MET A 477;GLY A 480;CYH A 481;LEU A 528;ASP A 539","None","0.87A","4hjoA-1k2pA:30.0","4hjoA-1k2pA:32.31"],["4KS8_A_B49A701_1","SERINE\/THREONINE-PROTEIN KINASE PAK 6","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"ALA A 428;VAL A 458;GLY A 480;LEU A 528;SER A 538;ASP A 539","None","0.84A","4ks8A-1k2pA:20.8","4ks8A-1k2pA:27.61"],["4L9I_A_8PRA601_1","RHODOPSIN KINASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"VAL A 416;ALA A 428;MET A 477;LEU A 528","None","0.67A","4l9iA-1k2pA:10.0","4l9iA-1k2pA:21.08"],["4L9I_B_8PRB601_1","RHODOPSIN KINASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",5,"VAL A 416;ALA A 428;LYS A 430;MET A 477;LEU A 528","None","0.72A","4l9iB-1k2pA:21.8","4l9iB-1k2pA:21.08"],["4MXO_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"ALA A 428;LYS A 430;VAL A 458;ILE A 472;THR A 474;TYR A 476;GLY A 480","None","0.65A","4mxoA-1k2pA:26.7","4mxoA-1k2pA:38.33"],["4MXO_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"ALA A 428;LYS A 430;VAL A 458;ILE A 472;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.65A","4mxoB-1k2pA:26.6","4mxoB-1k2pA:38.33"],["4MXO_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",9,"VAL A 416;ALA A 428;LYS A 430;VAL A 458;ILE A 472;TYR A 476;GLY A 480;LEU A 528;ASP A 539","None","0.88A","4mxoB-1k2pA:26.6","4mxoB-1k2pA:38.33"],["4MXX_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"ALA A 428;LYS A 430;VAL A 458;ILE A 472;TYR A 476;GLY A 480;LEU A 528","None","0.62A","4mxxA-1k2pA:26.7","4mxxA-1k2pA:38.33"],["4MXX_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"ALA A 428;LYS A 430;VAL A 458;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.59A","4mxxA-1k2pA:26.7","4mxxA-1k2pA:38.33"],["4MXX_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"ALA A 428;LYS A 430;VAL A 458;THR A 474;TYR A 476;MET A 477;GLY A 480;LEU A 528","None","0.65A","4mxxB-1k2pA:24.9","4mxxB-1k2pA:38.33"],["4MXX_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"VAL A 416;ALA A 428;LYS A 430;VAL A 458;TYR A 476;MET A 477;GLY A 480;LEU A 528","None","0.81A","4mxxB-1k2pA:24.9","4mxxB-1k2pA:38.33"],["4MXY_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"VAL A 416;ALA A 428;LYS A 430;VAL A 458;ILE A 472;TYR A 476;GLY A 480;LEU A 528","None","0.69A","4mxyA-1k2pA:25.8","4mxyA-1k2pA:37.63"],["4MXZ_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"VAL A 416;ALA A 428;LYS A 430;VAL A 458;ILE A 472;TYR A 476;GLY A 480;LEU A 528","None","0.69A","4mxzA-1k2pA:25.8","4mxzA-1k2pA:37.63"],["4O0S_A_ADNA500_1","AURORA KINASE A","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"LEU A 408;VAL A 416;ALA A 428;LYS A 430;ASN A 526;LEU A 528;ASP A 539","None","0.68A","4o0sA-1k2pA:15.4","4o0sA-1k2pA:25.61"],["4OTW_A_DB8A1101_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"VAL A 416;LYS A 430;VAL A 458;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.92A","4otwA-1k2pA:29.0","4otwA-1k2pA:28.44"],["4PCU_B_SAMB603_0","CYSTATHIONINE BETA-SYNTHASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",5,"PHE A 540;ASP A 539;VAL A 458;THR A 474;ILE A 472","None","1.45A","4pcuA-1k2pA:undetectable;4pcuB-1k2pA:0.0","4pcuA-1k2pA:18.77;4pcuB-1k2pA:18.77"],["4QRC_A_0LIA802_2","FIBROBLAST GROWTH FACTOR RECEPTOR 4","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",5,"LEU A 408;VAL A 416;LYS A 430;HIS A 519;LEU A 528","None","1.08A","4qrcA-1k2pA:27.9","4qrcA-1k2pA:33.75"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"ALA A 428;LYS A 430;ILE A 472;THR A 474;PHE A 540;GLY A 541","None","0.63A","4rzvA-1k2pA:8.1","4rzvA-1k2pA:30.77"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"VAL A 416;ALA A 428;LYS A 430;THR A 474;PHE A 540;GLY A 541","None","0.80A","4rzvB-1k2pA:28.2","4rzvB-1k2pA:30.77"],["4U0I_A_0LIA1001_2","MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"ALA A 428;LYS A 430;THR A 474;GLY A 480;HIS A 519;LEU A 528","None","0.64A","4u0iA-1k2pA:27.5","4u0iA-1k2pA:33.97"],["4UDA_A_DEXA1985_2","MINERALOCORTICOID RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"LEU A 483;LEU A 593;PHE A 493;VAL A 529","None","0.99A","4udaA-1k2pA:0.0","4udaA-1k2pA:22.02"],["4WA9_A_AXIA9000_1","TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"ALA A 428;THR A 474;MET A 477;GLY A 480;ASN A 526;LEU A 528","None","0.46A","4wa9A-1k2pA:29.8","4wa9A-1k2pA:45.26"],["4WA9_B_AXIB9000_1","TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"VAL A 416;ALA A 428;LYS A 430;THR A 474;MET A 477;GLY A 480;LEU A 528","None","0.79A","4wa9B-1k2pA:31.4","4wa9B-1k2pA:45.26"],["4WA9_B_AXIB9000_1","TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"VAL A 416;ALA A 428;THR A 474;MET A 477;GLY A 480;ASN A 526;LEU A 528","None","0.81A","4wa9B-1k2pA:31.4","4wa9B-1k2pA:45.26"],["4XEY_A_1N1A601_1","TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"ALA A 428;LYS A 430;VAL A 458;ILE A 472;THR A 474;GLY A 480;LEU A 528","None","0.69A","4xeyA-1k2pA:31.9","4xeyA-1k2pA:35.29"],["4XEY_A_1N1A601_1","TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"VAL A 416;ALA A 428;LYS A 430;VAL A 458;ILE A 472;GLY A 480;LEU A 528","None","0.76A","4xeyA-1k2pA:31.9","4xeyA-1k2pA:35.29"],["4XLI_A_1N1A601_1","NON-SPECIFIC PROTEIN-TYROSINE KINASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"ALA A 428;LYS A 430;VAL A 458;TYR A 476;MET A 477;GLY A 480;LEU A 528","None","0.64A","4xliA-1k2pA:32.0","4xliA-1k2pA:44.98"],["4XLI_A_1N1A601_1","NON-SPECIFIC PROTEIN-TYROSINE KINASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"ALA A 428;VAL A 458;THR A 474;TYR A 476;MET A 477;GLY A 480;LEU A 528","None","0.50A","4xliA-1k2pA:32.0","4xliA-1k2pA:44.98"],["4XLI_B_1N1B600_1","NON-SPECIFIC PROTEIN-TYROSINE KINASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"ALA A 428;LYS A 430;VAL A 458;ILE A 472;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.55A","4xliB-1k2pA:27.8","4xliB-1k2pA:44.98"],["4YSH_B_GLYB402_0","GLYCINE OXIDASE","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"MET A 449;GLU A 445;ARG A 520;ARG A 544","None","1.31A","4yshB-1k2pA:undetectable","4yshB-1k2pA:21.24"],["4ZAU_A_YY3A1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",5,"VAL A 416;ALA A 428;MET A 477;GLY A 480;CYH A 481","None","0.54A","4zauA-1k2pA:29.8","4zauA-1k2pA:33.02"],["5HES_A_032A401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"ALA A 428;ILE A 472;THR A 474;TYR A 476;PHE A 540;GLY A 541","None","0.80A","5hesA-1k2pA:10.0","5hesA-1k2pA:29.10"],["5HES_A_032A401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"VAL A 416;ALA A 428;ILE A 472;TYR A 476;PHE A 540;GLY A 541","None","0.73A","5hesA-1k2pA:10.0","5hesA-1k2pA:29.10"],["5HES_B_032B401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"VAL A 416;ALA A 428;LYS A 430;ILE A 472;THR A 474;TYR A 476;PHE A 540;GLY A 541","None","0.78A","5hesB-1k2pA:21.2","5hesB-1k2pA:29.10"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",5,"GLY A 411;VAL A 416;ALA A 428;LYS A 430;ILE A 472","None","0.88A","5hieB-1k2pA:25.7","5hieB-1k2pA:29.69"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",5,"VAL A 416;ALA A 428;LYS A 430;ILE A 472;THR A 474","None","0.83A","5hieD-1k2pA:25.9","5hieD-1k2pA:29.69"],["5I9X_A_DB8A1001_1","EPHRIN TYPE-A RECEPTOR 2","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"ALA A 428;ILE A 472;THR A 474;TYR A 476;GLY A 480;GLU A 488;LEU A 528;SER A 538","None","1.06A","5i9xA-1k2pA:28.7","5i9xA-1k2pA:39.46"],["5I9X_A_DB8A1001_1","EPHRIN TYPE-A RECEPTOR 2","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"ALA A 428;LYS A 430;ILE A 472;TYR A 476;GLY A 480;GLU A 488;LEU A 528;SER A 538","None","1.11A","5i9xA-1k2pA:28.7","5i9xA-1k2pA:39.46"],["5I9Y_A_1N1A1001_1","EPHRIN TYPE-A RECEPTOR 2","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"ALA A 428;LYS A 430;THR A 474;TYR A 476;GLY A 480;GLU A 488;LEU A 528","None","1.13A","5i9yA-1k2pA:24.4","5i9yA-1k2pA:39.46"],["5I9Y_A_1N1A1001_1","EPHRIN TYPE-A RECEPTOR 2","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"ALA A 428;THR A 474;TYR A 476;GLY A 480;GLU A 488;LEU A 528;SER A 538","None","1.06A","5i9yA-1k2pA:24.4","5i9yA-1k2pA:39.46"],["5MO4_A_NILA601_2","TYROSINE-PROTEIN KINASE ABL1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"ALA A 428;LEU A 457;VAL A 458;PHE A 517;HIS A 519;LEU A 528","None","0.62A","5mo4A-1k2pA:24.8","5mo4A-1k2pA:28.11"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"ALA A 428;MET A 449;ILE A 472;THR A 474;GLY A 480;ASN A 484;LEU A 528;PHE A 540","None","1.16A","5p9iA-1k2pA:33.6","5p9iA-1k2pA:100.00"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"ALA A 428;MET A 449;THR A 474;GLY A 480;ASN A 484;LEU A 528;SER A 538;PHE A 540","None","1.06A","5p9iA-1k2pA:33.6","5p9iA-1k2pA:100.00"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"GLY A 414;VAL A 416;ALA A 428;LYS A 430;ILE A 472;THR A 474;PHE A 540","None","1.17A","5p9iA-1k2pA:33.6","5p9iA-1k2pA:100.00"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"VAL A 416;ALA A 428;ILE A 472;THR A 474;GLY A 480;ASN A 484;LEU A 528;PHE A 540","None","1.25A","5p9iA-1k2pA:33.6","5p9iA-1k2pA:100.00"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"VAL A 416;ALA A 428;THR A 474;GLY A 480;ASN A 484;LEU A 528;SER A 538;PHE A 540","None","1.13A","5p9iA-1k2pA:33.6","5p9iA-1k2pA:100.00"],["5P9I_A_1E8A701_2","TYROSINE-PROTEIN KINASE BTK","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"LEU A 408;TYR A 476;MET A 477;CYH A 481","None","1.03A","5p9iA-1k2pA:33.6","5p9iA-1k2pA:100.00"],["5P9I_A_1E8A701_2","TYROSINE-PROTEIN KINASE BTK","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"TYR A 476;MET A 477;CYH A 481;ASP A 539","None","0.54A","5p9iA-1k2pA:33.6","5p9iA-1k2pA:100.00"],["5YU9_C_1E8C1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",6,"VAL A 416;ALA A 428;MET A 449;GLY A 480;CYH A 481;ASP A 539","None","0.89A","5yu9C-1k2pA:28.4","5yu9C-1k2pA:14.77"],["5YU9_D_1E8D1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",7,"VAL A 416;ALA A 428;MET A 449;GLY A 480;CYH A 481;LEU A 528;ASP A 539","None","0.83A","5yu9D-1k2pA:28.8","5yu9D-1k2pA:14.77"],["5ZMQ_I_PACI1_0","SERINE PROTEASE NS3;SERINE PROTEASE SUBUNIT NS2B;PEPTIDE PAC-DLY-DLY-DAR","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",3,"VAL A 448;TYR A 545;GLU A 444","None","0.94A","5zmqD-1k2pA:undetectable;5zmqE-1k2pA:undetectable","5zmqD-1k2pA:20.40;5zmqE-1k2pA:16.06"],["6BSD_A_1N1A901_0","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"VAL A 416;ALA A 428;LYS A 430;THR A 474;TYR A 476;MET A 477;GLY A 480;LEU A 528","None","0.69A","6bsdA-1k2pA:23.4","6bsdA-1k2pA:15.06"],["6E43_A_BEZA502_0","INDOLEAMINE 2,3-DIOXYGENASE 1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"LEU A 483;LEU A 486;ARG A 487;HIS A 491","None","1.01A","6e43A-1k2pA:0.0","6e43A-1k2pA:22.60"],["6E43_B_BEZB502_0","INDOLEAMINE 2,3-DIOXYGENASE 1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"LEU A 483;LEU A 486;ARG A 487;HIS A 491","None","1.03A","6e43B-1k2pA:0.0","6e43B-1k2pA:22.60"],["6E43_C_BEZC502_0","INDOLEAMINE 2,3-DIOXYGENASE 1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"LEU A 483;LEU A 486;ARG A 487;HIS A 491","None","1.01A","6e43C-1k2pA:0.0","6e43C-1k2pA:22.60"],["6E43_D_BEZD502_0","INDOLEAMINE 2,3-DIOXYGENASE 1","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",4,"LEU A 483;LEU A 486;ARG A 487;HIS A 491","None","0.99A","6e43D-1k2pA:0.0","6e43D-1k2pA:22.60"],["6FNM_A_1N1A1001_1","-","1k2p","TYROSINE-PROTEIN KINASE BTK","Homo sapiens",8,"ALA A 428;LYS A 430;ILE A 472;THR A 474;MET A 477;GLY A 480;LEU A 528;SER A 538","None","0.76A","6fnmA-1k2pA:26.0","6fnmA-1k2pA:36.58"]]